FDAk J&J COVID jab | Business and Economic News hopes to issue a new warning on

The U.S. FDA is expected to issue a new warning about Johnson & Johnson’s COVID-19 vaccine, linking it to a rare autoimmune disorder, the Washington Post reported Monday.

The U.S. Food and Drug Administration (FDA) is preparing to issue a new warning about Johnson & Johnson’s COVID-19 vaccine, linking it to a rare autoimmune disorder, the Washington Post reported Monday, citing four people who knew the subject.

The U.S. Centers for Disease Control and Prevention (CDC) said in a statement Monday that about 100 preliminary reports of Guillain-Barre syndrome have been found – a disorder affecting the immune system – after 12.8 million doses of J&J COVID. 19 jab in the US.

Most cases of rare disease were reported in people 50 years of age or older, usually two weeks after vaccination.

About 3,000 to 6,000 people in the U.S. develop Guillain-Barre syndrome each year. A completely misunderstood disease occurs after a virus or bacterial infection.

An increase in cases of Guillain-Barre syndrome was associated with swine flu vaccines in the 1970s, The Washington Post reported.

A new warning would be the final blow to J&J’s COVID vaccine. It requires a single jab and can be stored more easily than two mRNA vaccines developed by Moderna and Pfizer / BioNTech.

In April, the CDC and the FDA called for a step in the use of the J&J COVID-19 vaccine after it was linked to rare cases of severe blood clots, but lifted a temporary halt after determining that the benefits of the vaccine outweighed the risks.

J&J’s COVID-19 owner had production problems earlier this year, which dumped 75 million doses of the vaccine.

European regulators have also warned of a similar warning that AstraZeneca’s COVID-19 vaccine may increase the risk of Guillain-Barre syndrome.